In this Phase II, double-blind study, we evaluated hemagglutination-inhibition (HI) antibody responses with inactivated QIV (Fluarix™ Quadrivalent) and inactivated trivalent influenza vaccine ...

Its rival Moderna said earlier this month, however, that it has already fully enrolled a 6,000-subject phase 3 study of its quadrivalent vaccine candidate mRNA-1010 in the southern hemisphere ...

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza.